So here's a thing that happened Wednesday: cannabis stocks went absolutely bananas. We're talking double-digit percentage gains across the board. The reason? Axios reported that the Donald Trump administration is about to do something pretty significant—reclassify marijuana as a Schedule III drug, possibly as soon as today.
Think of it like this: the cannabis industry has been stuck in regulatory purgatory for years, and this move would be like opening a window. Not a door to full federal legalization, but a window that lets in some fresh air and, more importantly, some tax deductions.
The rally was everywhere. Shares of companies like Tilray Brands Inc (TLRY) and Canopy Growth Corp (CGC) shot up more than 15% and 23%, respectively. But the real action was in the exchange-traded funds (ETFs) that bundle these companies together. The AdvisorShares Pure US Cannabis ETF (MSOS) jumped more than 25%. The AdvisorShares Pure Cannabis ETF (YOLO) gained around 18%. The Amplify Alternative Harvest ETF (MJ) climbed over 22%. And the Amplify Seymour Cannabis ETF (CNBS) posted strong gains of more than 24%. That's a lot of green on the screen for a sector that's been mostly red for a long time.
So why does a reclassification matter so much? It's all about the tax code, specifically a provision called Section 280E. Right now, marijuana is a Schedule I drug, which the government says has no accepted medical use and a high potential for abuse. That classification means U.S. cannabis companies—the multi-state operators (MSOs) that are the backbone of funds like MSOS—can't deduct ordinary business expenses. Things like rent, payroll, marketing. They pay taxes on their gross profit, which is a brutal way to run a business.
Moving marijuana to Schedule III would put it in the same category as drugs with accepted medical use but some abuse potential, like ketamine or anabolic steroids. It wouldn't make it legal federally, but it would very likely remove that 280E shackle. Suddenly, these companies could start deducting expenses like everyone else. Their profitability would get a meaningful, maybe even transformative, boost.
This is why ETFs are back in focus. Many of these funds have been stuck in a rut for years—weak investor flows, low liquidity, just generally being ignored. A policy shift like this changes the math. For funds with heavy U.S. exposure, like MSOS, it directly improves the earnings outlook for their biggest holdings. That could finally attract the institutional money that's been sitting on the sidelines, scared off by the regulatory fog.
Even the more diversified funds like YOLO and MJ, which mix U.S. operators with Canadian players like Tilray and Canopy, stand to benefit. When sentiment improves for the whole sector, money tends to flow in more broadly.
The big question now is whether this is just a one-day wonder, a tactical trade on a news headline, or the start of something more durable. For a sector that many investors had written off as "dead money," this could be the catalyst for a structural turnaround. A shift to Schedule III could unlock more research coverage, make these stocks eligible for more investment portfolios, and improve access to capital. It could help cannabis ETFs graduate from being purely speculative bets to investments with clearer fundamental support.
Of course, uncertainties remain. The timing and exact implementation details aren't set in stone. But the market's reaction on Wednesday was pretty clear: investors are placing their bets early, hoping this is the regulatory inflection point that finally breathes some life back into the cannabis trade.
